The American Pharmaceutical Group (APG) was set up in 1985 to improve understanding of the industry, and the healthcare contribution of the American companies in particular, among Government, Parliamentarians and interested stakeholders.

The APG works closely with the industry’s trade body, the Association of the British Pharmaceutical Industry, but with the US being the most competitive market for medicines in the world and accounting for over half of the developed world’s R&D, the APG is able to add a special perspective.

The APG represents the leading US owned companies which together form the largest national grouping within the UK-based pharmaceutical industry. The member companies are significant investors and employers in the UK, and make a major contribution to the NHS.

Member Companies

  • APG member companies invest more than £1.2 billion annually in the UK (based on 8 member contributions)
  • £792 million of this is invested in research and development alone (based on 8 member contributions)
  • This represents 13 per cent of the total spend by pharmaceutical companies in the UK (based on 5 member contributions)
  • The APG employ more than 14,000 people in highly skilled jobs. Each life sciences position supports 3.4 jobs elsewhere in the UK economy; this equates to 50,000 roles in total that link back to APG employers (based on 8 member contributions)
  • APG members have been responsible for launching over 20 new medicines in the UK between 2011 and 2015 (based on 4 member contributions)
  • In 2017 alone, the APG is conducting more than 500 clinical trials in the UK, providing over 24,000 patients with the opportunity to benefit from innovative medicines (based on 9 member contributions)
  • 40 UK sites covering manufacturing, research, packaging and commercial operations

Further details about the individual member companies can be found in the section on members.